Leadership Overview
Jazz Pharmaceuticals has 6 executives leading key functions including strategy, research and development, and human resources.
Driven by a commitment to innovation, Jazz Pharmaceuticals focuses on developing transformative therapies for patients with serious unmet medical needs in neuroscience and oncology.
Driven by a commitment to innovation, Jazz Pharmaceuticals focuses on developing transformative therapies for patients with serious unmet medical needs in neuroscience and oncology.
Leadership Roles at Jazz Pharmaceuticals
Bruce Cozadd - Chairperson and Chief Executive Officer
Bruce Cozadd, the Chairperson and Chief Executive Officer at Jazz Pharmaceuticals, directs the company's overarching strategy and operational execution. Overseeing global operations, Cozadd ensures alignment with the company's mission to develop and deliver life-changing medicines. This leadership role involves guiding the biopharmaceutical firm's expansion in neuroscience and oncology markets. By driving strategic initiatives, Bruce Cozadd directly impacts the company's growth and market position. Ultimately, Cozadd secures long-term financial stability and fosters a culture of innovation across the organization. The Chairperson and Chief Executive Officer's vision shapes the company's direction, focusing on addressing critical patient needs through scientific advancement and commercial excellence. This executive's purview extends to all facets of the business, from research and development pipelines to market access and patient support programs, ensuring a cohesive and impactful approach to healthcare solutions.
Taryn Stinson - Director, Chief of Staff To the Chief Financial Officer
Taryn Stinson, the Director, Chief of Staff To the Chief Financial Officer at Jazz Pharmaceuticals, provides critical support to the CFO in managing financial operations and strategic planning. Stinson facilitates communication and coordination across finance departments, ensuring efficient execution of fiscal strategies. This position involves overseeing key financial projects and driving improvements in financial reporting and analysis. By streamlining financial processes, Taryn Stinson directly enhances the company's fiscal discipline and decision-making capabilities. The Director, Chief of Staff To the Chief Financial Officer's focus extends to supporting the financial health of Jazz Pharmaceuticals, particularly in its expansion within the biopharmaceutical sector. This executive's role is integral to maintaining robust financial oversight and supporting the company's mission in neuroscience and oncology.
Kimberly Chaney - HR Chief of Staff
Kimberly Chaney, the HR Chief of Staff at Jazz Pharmaceuticals, supports the strategic direction and operational efficiency of the human resources function. Collaborating closely with senior leadership, Chaney ensures HR initiatives align with the company's business objectives and employee development goals. This role involves managing key projects and driving process improvements within the people operations department. By optimizing HR strategies, Kimberly Chaney directly contributes to fostering a high-performing and engaged workforce. The HR Chief of Staff's efforts focus on enhancing organizational culture and supporting talent management across Jazz Pharmaceuticals' global operations. This executive's responsibilities include facilitating communication between HR leadership and other departments, ensuring seamless execution of people-centric programs that support the company's growth in neuroscience and oncology.
Arthur Louie - Chief Medical Officer
Arthur Louie, the Chief Medical Officer at Jazz Pharmaceuticals, directs the company's clinical development and medical affairs strategies. Overseeing all medical operations, Louie ensures that research and development efforts align with patient needs and regulatory requirements in neuroscience and oncology. This leadership role involves guiding the scientific direction of the biopharmaceutical firm's product pipeline. By driving clinical excellence, Arthur Louie directly impacts the successful advancement of new therapies. The Chief Medical Officer's vision shapes the company's approach to medical innovation, focusing on addressing serious unmet medical needs. This executive's responsibilities include leading clinical trial design, medical education, and ensuring the safety and efficacy of Jazz Pharmaceuticals' portfolio.
Heidi Manna - Executive Vice President & Chief People Officer
Heidi Manna, the Executive Vice President & Chief People Officer at Jazz Pharmaceuticals, leads the global human resources strategy and operations. Manna drives initiatives focused on talent acquisition, development, and retention, ensuring a robust and engaged workforce to support the company's growth in neuroscience and oncology. This executive role involves cultivating a strong organizational culture that fosters innovation and collaboration across all departments. By championing people-centric policies, Heidi Manna directly enhances employee experience and organizational effectiveness. The Executive Vice President & Chief People Officer's strategic oversight ensures that Jazz Pharmaceuticals attracts and retains top talent essential for developing transformative therapies. This leadership position is critical in aligning HR functions with the company's mission to address serious unmet medical needs.
Robert Iannone - Executive Vice President & Global Chief Medical Officer, Head of Research Development
Robert Iannone, the Executive Vice President & Global Chief Medical Officer, Head of Research Development at Jazz Pharmaceuticals, spearheads the company's research and development pipeline. Iannone directs the scientific strategy for discovering and advancing novel therapies in neuroscience and oncology, ensuring alignment with global medical standards. This critical role involves overseeing all aspects of research, from early-stage discovery to late-stage clinical trials. By driving innovation in drug development, Robert Iannone directly contributes to Jazz Pharmaceuticals' mission of addressing serious unmet medical needs. The Executive Vice President & Global Chief Medical Officer, Head of Research Development's leadership is fundamental to expanding the company's therapeutic offerings and solidifying its position as a leader in biopharmaceuticals. This executive's expertise guides the scientific direction and execution of R&D programs.
Explore Leadership Teams in Manufacturing
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company is headquartered in Tokyo, Japan
Company Leadership RR
DB
WH
FD
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions.
Company Leadership
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
SG
SP
CS
Founded in 1969, Themis Medicar is a pharmaceutical company that specializes in manufacturing pharmaceuticals and medicinal chemicals for cardiology, pain management, anti-infectives, haematinics, and health and nutrition. Themis Medicare is located in India.
Company Leadership PN
TD
MS
HM
Frequently Asked Questions Regarding Jazz Pharmaceuticals Top Executives and Leadership Team
Unlock more people and company data
